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Abstract: Vitamin D deficiency is a worldwide health problem that, in addition to its well-known
negative effects on musculoskeletal health, has been related to a wide range of acute and chronic
age-related diseases. However, little is known about the association of body composition with the
active, hormonal form of vitamin D, 1,25-dihydroxyvitamin D plasma levels (1,25(OH)2D). Therefore,
the aim of this study was to investigate the association of 1,25(OH)2D with body composition including
lean and fat body mass as well as bone mineral density (BMD) in middle-aged sedentary adults. A total
of 73 (39 women) middle-aged sedentary adults (53.7 ± 5.1 years old) participated in the current study.
We measured weight and height, and we used dual energy X-ray absorptiometry to measure lean body
mass, fat body mass and BMD. Body mass index (BMI), lean mass index (LMI), and fat mass index (FMI)
were calculated. 1,25(OH)2D was measured using a DiaSorin Liaison®immunochemiluminometric
analyzer. The results showed a negative association of 1,25(OH)2D with BMI, LMI and BMD
(β = −0.274, R2 = 0.075, p = 0.019; β = −0.268, R2 = 0.072, p = 0.022; and β = −0.325, R2 = 0.105,
p = 0.005, respectively), which persisted after controlling for age and sex. No significant differences in
1,25(OH)2D across body weight status were observed after controlling for the same covariates. In
summary, our results suggest that 1,25(OH)2D could be negatively associated with BMI, LMI and
BMD whereas no association was found with FMI in middle-aged sedentary adults.
Keywords: vitamin D; calcitriol; body mass index; lean mass; fat mass; bone mineral density
1. Introduction
As the world´s population ages, the prevalence of chronic diseases increases, particularly over
the last decades, becoming one of the great challenges that society faces [1,2]. Abnormalities in body
composition such as a decrease of lean body mass and/or bone mineral density (BMD) or an increment
in fat body mass are powerful predictors of morbidity and mortality risk as well as overall quality
of life [3]. Epidemiologic studies indicate that these body composition changes are closely related to
obesity, sarcopenia and/or osteoporosis in the elderly population [3,4]. However, these chronic diseases
are progressive and initiate at a younger age [5,6]. Their high prevalence and concomitant health
risk make them a particularly relevant worldwide public health problem and a social and economic
burden [7–9].
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Vitamin D is a fat-soluble vitamin essential for normal homeostasis of calcium and phosphorus, as
well as for bone health [10] and preventing falls [11] and fractures [12]. Globally, vitamin D deficiency
has been considered as a major public health problem affecting not only musculoskeletal health
but also a wide range of several age-related chronic diseases [13]. 25-hydroxyvitamin D (25(OH)D)
is the most commonly used biomarker when evaluating the relationship of vitamin D status with
health-related outcomes [14–17]. However, 25(OH)D is thought to be largely inactive since it requires
to be metabolized in the kidney by the enzyme 25-hydroxyvitamin D-1α-hydroxylase to be active.
Therefore, 1,25-dihydroxyvitamin D (1,25(OH)2D), also known as calcitriol, is responsible for most, if
not all, of its biological effects [18,19]. The association between 1,25(OH)2D and body composition
parameters has been hard to establish for several reasons: (i) previously there was not a reliable and
sensitive assay for calcitriol [20,21] and (ii) 25(OH)D has a higher concentration and longer half-life
than 1,25(OH)2D, thus requiring less sample volume for reliable measurements [22].
Consequently, epidemiological data are scarce, and a review of the scientific literature found
no large studies examining the relationship between 1,25(OH)2D and body composition outcomes.
There is some evidence of the existence of an inverse association of 1,25(OH)2D with body mass index
(BMI) and fat body mass [23,24], however these data are conflicting with other studies [25–28]. In
contrast, data are scarce on the potential relationship between 1,25(OH)2D and lean body mass. Two
recent studies found a significant association between low 1,25(OH)2D and low lean body mass [29,30],
which is highly dependent on the individual’s age [29]. Similarly, controversial findings have been
discovered regarding the role of 1,25(OH)2D in bone health. Previous cross-sectional studies have
reported an inverse association between 1,25(OH)2D and BMD [31–33], whereas other studies found
that 1,25(OH)2D was unrelated to bone mineral content [34], bone loss [33,35] or hip fracture risk [36,37].
There are limited data on the study of body composition parameters in relation to 1,25(OH)2D
status in middle-aged adults. Thus, understanding whether 1,25(OH)2D is associated with body
composition parameters in this population is of clinical interest since, as previously established, the
interventions to delay or reverse body composition related diseases are preferable when individuals
are still relatively young and healthy [38,39].
Therefore, the aim of this study was to investigate the association of 1,25(OH)2D with body
composition including lean and fat body mass as well as BMD in middle-aged sedentary adults.
2. Materials and Methods
2.1. Study Design and Participants
The present cross-sectional study was conducted under the framework of the FIT-AGEING study
(clinicaltrial.gov: ID: NCT03334357) [40]. The Ethics Committee on Human Research of the Regional
Government of Andalucía approved the rationale, design, and methodology of the study [0838-N-2017]
and all participants signed written informed consent in accordance with the Declaration of Helsinki
(last revision guidelines, 2013).
Seventy-three middle-aged sedentary adults were recruited via electronic media, social networks
and leaflets. The inclusion criteria were as follows: (i) to be sedentary (i.e., less than 20 min of
physical activity on less than 3 days/week), (ii) not to have had greater body weight changes than
3 kg in the past 3 months, (iii) to be aged between 45 and 65 years old, (iv) not to be a smoker, (v) to
be taking no long-term medication, (vi) not to be pregnant and (vii) not to suffer from any chronic
cardiometabolic disease.
All tests were performed during September–October 2016/17 at the Sport and Health University
Research Institute (iMUDS, Granada, Spain) and at the “Campus de la Salud” Hospital (Granada, Spain).
2.2. Anthropometric Parameters and Body Composition Assessment
A pre-validated Seca model 799 scale and stadiometer (Seca, Hamburg, Germany) was used
to measure body weight and height with light clothing and without shoes. BMI was subsequently
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calculated as weight (kg)/height (m2). Body composition outcomes were determined by a dual-energy
X-ray absorptiometry scanner (Discovery Wi, Hologic, Inc., Bedford, MA, USA) obtaining lean body
mass in kg, fat body mass in kg, and BMD in g/cm2. A spine phantom quality check scan was conducted
on each study day. A whole-body scan was performed considering all manufacturer´s guidelines
(i.e., the positioning of participants, the analysis of results and the quality controls among others).
The APEX 4.0.2. software was used to draw an automatic delineation of anatomic regions. The lean
mass index (LMI) was calculated as lean body mass (kg)/body height (m2). Similarly, we calculated
the fat mass index (FMI) as fat body mass (kg)/body height (m2). Fat mass was also expressed as a
percentage of the total body mass. The participants were categorized into three groups on the basis of
BMI levels: (i) normal weight (BMI ≥ 18.5 and <25 kg/m2), (ii) overweight (BMI ≥ 25 and <30 kg/m2),
and (iii) obese (BMI ≥ 30 kg/m2).
2.3. Dietary Intake Assessment
We performed a total of three 24-hour dietary recalls collected on non-consecutive days (one
weekend day included). This validated method is able to determine the energy intake to within 8–10%
of the current energy intake [41]. The interviews were meal sequence-based, in which a detailed
description of the food consumed by the participants was recorded. The 24-hour dietary recalls were
collected by an experimented and qualified research dietitian (L.J.-F.), using a photograph guide to
improve the quality of the information provided on portion sizes of food and assisting participants in
the estimation of the consumed food quantity [42]. The software EvalFINUT® updated with data from
USDA (U.S. Department of Agriculture) and BEDCA (“Base de Datos Española de Composición de
Alimentos”) was used to calculate energy and micronutrient (i.e., vitamin D, calcium and phosphorus)
intake derived from the 24-hour recalls.
2.4. Physical Activity Assessment
Physical activity levels were objectively assessed with a wrist-worn accelerometer (ActiGraph
GT3X+, Pensacola, FL, United States) for 7 consecutive days (24 hours/day) [40]. The sampling
frequency was previously set at 100 Hz to store raw accelerations [43]. The ActiLife v.6.13.3 software
(ActiGraph, Pensacola, FL, United States) and the GGIR package (v.1.5-122) in R (v.3.1.23) were used
to process these files [44,45]. The participants came to the laboratory and specific information about
how to wear the accelerometer was given. They were also reminded to remove it only during
water-based activities such as swimming or bathing. Only the participants who wore the accelerometer
for ≥16 hours/day for 4 days (including 1 weekend day) were included in the analysis.
2.5. Blood Samples Assessment
A 10 mL peripheral blood sample was taken from the antecubital vein after overnight fasting. It
was collected using the Vacutainer SST system (Becton Dickinson, Plymouth, UK) in ethylenediamine
tetra-acetic acid-containing tubes. Blood samples were centrifuged at four thousand revolution per
minute for seven minutes at 4 ◦C and stored at −80 ◦C. Plasma levels of 1,25(OH)2D were measured
using a DiaSorin Liaison®immunochemiluminometric analyzer (DiaSorin Ltd, Wokingham, Berkshire,
UK) and expressed in pg/mL.
2.6. Statistical Analysis
Data were checked for normality with the use of distribution plots (i.e., visual check of histograms,
and Q-Q plots) and the Shapiro-Wilk test. The descriptive parameters were reported as mean and
standard deviation.
Differences between sexes were examined using an independent samples T test. Given that
no interaction for sex was observed (p > 0.05), data are presented for men and women together.
Simple linear regression models were built to test the association of 1,25(OH)2D and body composition
outcomes (i.e., BMI, LMI, FMI, and BMD). We also performed multiple linear regression models to
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analyze these associations controlling for age (Model 1), sex (Model 2), and age and sex (Model 3).
Additionally, we also adjusted these models for total energy, vitamin D, calcium, phosphorus intake
and/or physical activity levels (i.e., light, moderate-vigorous and total physical activity). To test
whether 1,25(OH)2D was different across body weight status (i.e., normal-weight, overweight and
obese individuals), an analysis of variance (ANOVA) was conducted. Moreover, we performed an
analysis of covariance to test the differences of 1,25(OH)2D across weight status adjusting for age
and sex.
Data were analyzed with the use of the Statistical Package for Social Sciences (SPSS, v. 22.0, IBM
SPSS Statistics, IBM Corporation, Armonk, NY, USA). Graphical plots were built using the GraphPad
Prism 5 (GraphPad Software, San Diego, CA, USA). The level of significance was fixed at <0.05.
3. Results
Table 1 shows the descriptive parameters of our study participants by sex. No significant
differences in 1,25(OH)2D were observed between men and women (p = 0.576).
Table 1. Descriptive characteristics of participants.
N All N Men N Women
Age (years) 73 53.7 (5.1) 34 54.6 (5.2) 39 53 (5.0)
Body composition parameters
Body mass index (kg/m2) 73 26.7 (3.8) 34 28.3 (3.6) 39 25.3 (3.3) *
Lean mass (kg) 73 43.2 (11.7) 34 53.9 (6.5) 39 34.1 (5.8) *
Lean mass index (kg/m2) 73 15.2 (2.9) 34 17.5 (2.0) 39 13.2 (1.8) *
Fat mass (%) 73 40.1 (8.9) 34 34.7 (8.0) 39 44.5 (7.4) *
Fat mass (kg) 73 30.1 (8.5) 34 30.9 (9.8) 39 29.2 (7.1)
Fat mass index (kg/m2) 73 10.8 (3.1) 34 10.0 (3.2) 39 11.4 (2.9)
Bone mineral density (g/cm2) 73 1.1 (0.1) 34 1.2 (0.1) 39 1.0 (0.1) *
Dietary intake
Total Energy intake (kcal/day) 72 2071.7 (455.4) 34 2312.1 (402.9) 38 1854.6 (390.3) *
Vitamin D intake (µg/day) 72 5.0 (6.0) 34 3.8 (3.3) 38 6.1 (7.6)
Calcium intake (mg/day) 72 763.4 (340.5) 34 867.3 (396.9) 38 670.5 (251.4) *
Phosphorus intake (mg/day) 72 1324.7 (558.9) 34 1507.6 (689.6) 38 1161.0 (342.2) *
Physical activity parameters
LPA (min/day) 70 173.7 (45.4) 33 169.9 (52.7) 37 178.0 (40.7)
MVPA (min/day) 70 95.8 (35.6) 33 96.4 (37.1) 37 96.6 (35.7)
Total PA (min/day) 70 269.5 (75.1) 33 265.2 (79.3) 37 273.3 (72.0)
Blood parameters
1,25 Dihydroxyvitamin D (pg/ml) 73 40.3 (14.1) 34 38.3 (13.4) 39 42.0 (14.6)
Dara are presented as means (standard deviation). Abbreviations: LPA, light physical activity; MVPA,
moderate-vigorous physical activity; PA, physical activity. * Significance differences between sexes (p < 0.05)
obtained by the independent sample T test.
Figure 1 shows the associations between 1,25(OH)2D and body composition related parameters.
There was a significant negative association of 1,25(OH)2D with BMI (β = −0.274, R2 = 0.075, p = 0.019,
Figure 1A), LMI (β = −0.268, R2 = 0.072, p = 0.022, Figure 1B) and BMD (β = −0.325, R2 = 0.105,
p = 0.005, Figure 1D), which persisted after including age, sex, and age and sex in the model (all
p ≤ 0.042, Table 2). 1,25(OH)2D was not significantly associated with FMI (β = −0.080, R2 = 0.006,
p = 0.502; Figure 1C), which did not change adjusting for age, sex, and age and sex (all p ≥ 0.35,
Table 2). The results remained unchanged after further adjusting for total energy, vitamin D, calcium,
phosphorus intake and/or physical activity levels (i.e., light, moderate-vigorous and total physical
activity) (data not shown, all p > 0.1).
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Figure 1. Simple linear regression graphs between 1,25-Dihydroxyvitamin D (1,25(OH)2D) and body
mass index (BMI) (A), lean mass index (LMI) (B), fat mass index (FMI) (C), and bone mineral density
(BMD) (D) in middle-aged sedentary adults. β (standardized regression coefficient), R2, and P from a
simple linear regression analysis.
Table 2. Association of 1,25-Dihydroxyvitamin D with body mass index, lean mass index, fat mass
index and bone mineral density.
1,25-Dihydroxyvitamin D
Model 1 Model 2 Model 3
p value β p value β p value β
Body mass index (kg/m2) 0.020 −0.274 0.040 −0.263 0.042 −0.262
Lean mass index (kg/m2) 0.023 −0.269 0.030 −0.383 0.032 −0.383
Fat mass index (kg/m2) 0.505 −0.080 0.354 −0.112 0.356 −0.113
Bone mineral density (g/cm2) 0.005 −0.325 0.009 −0.370 0.009 −0.377
Model 1 was adjusted for age; Model 2 was adjusted for sex; and Model 3 was adjusted for age and sex. p value of
multiple-regression analysis. β (standardized regression coefficient). Values in bold indicate significance differences
(p < 0.05).
ANOVA revealed no significant differences in 1,25(OH)2D across body weight status
(45.3 ± 13.3 pg/mL in normal-weight, 37.8 ± 13.1 pg/mL in overweight and 38.4 ± 16.7 pg/mL in obese
individuals; Figure 2), which persisted after including age and sex as a covariate (44.8 ± 13.1 pg/mL in
normal-weight; 37.9 ± 12.3 pg/mL in overweight and 38.9 ± 14.0 in obese individuals; p = 0.2).
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Figure 2. 1,25-Dihydroxyvitamin D (1,25(OH)2 ) by body weight status categories in middle-aged
adults. Values are presented as means and standard error. p value obtained from the analysis of the
variance to compare 1,25(OH)2D across weight status (normal-weight, over-weight, and obese).
4. Discussion
The main results of the pr sent study suggest that 1,25(OH)2D i negatively associated with BMI,
LMI and BMD independently of age and sex, whereas no association was found between 1,25(OH)2D
and FMI in middle-aged sedentary adults.
There is a controversy i the sci tific literatur regarding the 1,25(OH)2D status of obese
individuals. It ha been described in classical studies that here ar greater levels of 1,25(OH)2D
(~20 to 30%) in both obese men and women [25–28,46]. However, although we did not find any
significant differences between BMI groups, we observed that overweight and obese individuals have
~16.6% and ~15.3% lower 1,25(OH)2 than normal-weight individuals, which agrees with a previous
large cohort t at report d a ~18% low r 1,25(OH)2D in the obese group compared ith their lean
counterparts [23,24]. These discrepancies between studies cannot be attributed to the individual´s age,
sex and/or BMI, since the participants had similar biological characteristics. A seasonal effect might
explain these controversi l r sults as the 1,25(OH)2D assessm nt was conducted in winter months [46]
or spring months [27] in some studies, while others did not control the seaso in which the blood
samples were taken [24]. Given that the effects of ultraviolet ray exposure on 25(OH)D could be
different for obese and lean individuals, the time of the year when the study was conducted may
be of importance. However, pr vious studies have suggest d that th sea on of t e y ar does not
present the same influence on 1,25(OH)2D as it has on 25(OH)D [47]. The different 1,25(OH)2D assay
methods used across the studies could be one important factor to consider. While older studies applied
radioreceptor assays [25–28,46] in which lipid interferences have been described when samples are
not pure enough [48], more r cent studies including our own study used modern immuno assays for
the assessment of 1,25(OH)2D [30,32]. Taken ll together, it is likely that obese subjects present low
1,25(OH)2D. This fact could be explained because obesity is associated with poor levels of 25(OH)D,
and it has been demonstrated that 1,25(OH)2D depends on substrate availability [23,49]. A higher fat
body mass offers a greater distribution space for both fat-soluble compounds. Additionally, obese
individuals are usually exposed to negative lifestyle factors (i.e., unhealthy dietary habits and sedentary
behaviour, among others), [50] and to lower sunlight exposure [51]. These lifestyle factors have been
shown to have a negative influence on vitamin D status [52,53].
The use of 25(OH)D as a key marker of vitamin D status has logical advantages summarized as
greater serum stability and a longer half-life than other markers (e.g., 1,25(OH)2D) [22]. However,
it is important to consider that it is biologically inactive and therefore could not be the best vitamin
D function indicator [54]. The shorter half-life of 1,25(OH)2D could be one of the reasons why the
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relationship of 1,25(OH)2D and lean body mass has not been deeply studied. Hassan-Smith et al.
reported a positive association between 1,25(OH)2D and lean body mass [29]. These findings differ
from those observed in our study in which we obtained higher 1,25(OH)2D in individuals with lower
lean body mass. These discrepancies could be explained by the different biological characteristics of
the subjects of the study (i.e., our cohort was older than the Hassan-Smith et al. study [29]) and by
the different assay methods used to determine 1,25(OH)2D. New studies measuring 1,25(OH)2D are
necessary to clarify this issue.
We also found a negative association between 1,25(OH)2D and BMD in our study cohort which
concurs with a previous study that reported a positive association of 1,25(OH)2D and the bone
resorption marker β-cTX [32]. These results are consistent with the notion that 1,25(OH)2D increases
bone resorption via stimulating intestinal calcium absorption after calcium intake [32]. Moreover,
recent animal and in vitro studies have proposed that 1,25(OH)2D has a direct effect on osteoclasts
inducing bone resorption by its interaction with the receptor activator of nuclear factor-κβ/receptor
activator of nuclear factor-κβ ligand signaling pathway [55,56]. Taking this into consideration, an
inverse association would be expected between 1,25(OH)2D and bone mineral density. In addition, it
seems plausible that 1,25(OH)2D is produced when BMD is low and once BMD is recovered 25 (OH)D
is transformed into the inactive 24,25(OH)2D. Although this argument could explain our findings,
further intervention studies are needed to understand this issue.
Our study has some limitations. The cross-sectional design does not allow ascribing causality to the
observed relationships. Further, our study population was limited to sedentary healthy middle-aged
adults (45–65 years old) and hence these results may not be generalizable to younger, older, and/or
physically active individuals. This study, like most clinical studies, was based on a single assay of
1,25(OH)2D. We did not assess the 24-hydroxyvitamin D2 plasma levels. In addition, a whole-body
DXA scan was conducted, so future studies are necessary to investigate whether spine and hip bone
mineral density have the same association pattern. Finally, due to the relatively small sample size of
the current study, the data should be interpreted with caution. One of the strengths of this study is
that body composition was measured using a gold-standard technology, such as dual-energy X-ray
absorptiometry. In addition, the measurement of objective physical activity data and dietary intake to
be used as covariates represent further strengths.
5. Conclusions
In conclusion, our results suggest that 1,25(OH)2D could be negatively associated with BMI,
LMI and BMD independently of age and sex, while no significant relationship was obtained
between 1,25(OH)2D and FMI in middle-aged sedentary adults. Intervention studies are needed to
understand whether changes in body composition status are associated with changes in 1,25(OH)2D in
this age-population.
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